Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Non-cash Items (2022 - 2024)

Historic Non-cash Items for BioNexus Gene Lab (BGLC) over the last 3 years, with Q4 2024 value amounting to -$508330.0.

  • BioNexus Gene Lab's Non-cash Items rose 3605.66% to -$508330.0 in Q4 2024 from the same period last year, while for Dec 2024 it was -$2.3 million, marking a year-over-year decrease of 2110.45%. This contributed to the annual value of -$2.3 million for FY2024, which is 2110.45% down from last year.
  • Per BioNexus Gene Lab's latest filing, its Non-cash Items stood at -$508330.0 for Q4 2024, which was up 3605.66% from -$1.5 million recorded in Q3 2024.
  • BioNexus Gene Lab's Non-cash Items' 5-year high stood at $40263.0 during Q1 2022, with a 5-year trough of -$1.5 million in Q3 2024.
  • Its 3-year average for Non-cash Items is -$391636.8, with a median of -$88513.0 in 2023.
  • Its Non-cash Items has fluctuated over the past 5 years, first plummeted by 4488989.31% in 2023, then skyrocketed by 5666.4% in 2024.
  • BioNexus Gene Lab's Non-cash Items (Quarter) stood at $2246.0 in 2022, then tumbled by 35494.88% to -$794969.0 in 2023, then skyrocketed by 36.06% to -$508330.0 in 2024.
  • Its Non-cash Items stands at -$508330.0 for Q4 2024, versus -$1.5 million for Q3 2024 and -$344207.0 for Q2 2024.